Ask AI
MASH Matters GI and Hepatology Practice

CE / CME

MASH Matters: New Evidence and Its Application to Gastroenterology and Hepatology Practice

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: June 23, 2025

Expiration: June 22, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Sheth S. Steatotic liver disease: cutting through the fat. aasld.org/liver-fellow-network/core-series/back-basics/steatotic-liver-disease-cutting-through-fat. Accessed June 17, 2025.
  2. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-1986.
  3. Le P, Tatar M, Dasarathy S, et al. Estimated burden of metabolic dysfunction–associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707.
  4. Younossi ZM. Non-alcoholic fatty liver disease: a global public health perspective. J Hepatol. 2019;70:531-544.
  5. Kabbany MN, Conjeevaram Selvakumar PK, et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey data. Am J Gastroenterol. 2017;112:581-587.
  6. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32-S50.
  7. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2019;1:312-328.
  8. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657-1669.
  9. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025 May 28:dci240094.
  10. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-1835.
  11. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S59-S85.
  12. Resmetirom [prescribing information]. West Conshohocken, PA: Madrigal; 2024.
  13. Abushamat LA, Shah PA, Eckel RH, et al. The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol. 2024;22:1565-1574.
  14. Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023;44:14-32.
  15. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-2099.
  16. National Archives. Code of federal regulations. ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-H. Accessed June 17, 2025.
  17. Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018;14:259-269.
  18. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
  19. Cooreman MP, Butler J, Giugliano RP, et al. The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis. Nature Communications. 2024;15:3962.
  20. Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547-1558.
  21. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311-319.
  22. Szczepańska E, Gietka-Czernel M. FGF21: a novel regulator of glucose and lipid metabolism and whole-body energy balance. Horm Metab Res. 2022;54:203-211.
  23. Noureddin. AASLD 2024. Abstr 5021.
  24. Noureddin M, Rinella ME, Chalasani NP, et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N Engl J Med. 2025;[Epub ahead of print].
  25. Once-monthly efimosfermin alfa (BOS-580) in metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial. Gastroenterol Hepatol (N Y). 2024;20(12 Suppl 11):15-16.
  26. Melson E, Ashraf U, Papamargaritis D, et al. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025;49:433-451.
  27. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.